Trial reportBlood2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Registry-linked trialAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01207440 (A Pivotal Phase 2 Trial of Ponatinib), which is not on this map. Cited by 333 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
333citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
Who cites it
333 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- [Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Guideline
- Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.International journal of molecular sciences · 2024Pooled it
- Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches.Clinical drug investigation · 2024Pooled it
- Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison.Frontiers in oncology · 2024Pooled it
- Trial
- One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.Annals of hematology · 2026Trial
- Sitz bath with different concentrations of diluted povidone-iodine for prevention of perianal infection in patients with hematological malignancies undergoing chemotherapy: a randomized controlled trial in a tertiary hospital in China.Frontiers in public health · 2026Trial
- Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib.Annals of hematology · 2025Trial
- Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.Blood advances · 2025Trial
- Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.Clinical and translational science · 2025Trial
- Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.The Lancet. Haematology · 2024Trial
- Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.Leukemia · 2024Trial
- Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.International journal of hematology · 2024Trial
- Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?Haematologica · 2023Trial
- Trial
- Trial
- Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.Journal of hematology & oncology · 2022Trial
- A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy.Leukemia · 2022Trial
- Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood advances · 2022Trial
- Article
273 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Jorge E CortesThe University of Texas MD Anderson Cancer Center, Houston, TX.
Dong-Wook KimSeoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea.
Javier Pinilla-IbarzH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
Philipp D le CoutreCharité, Universitätsmedizin Berlin, Berlin, Germany.
Ronald PaquetteCedars-Sinai Medical Center, Los Angeles, CA.
Charles ChuahSingapore General Hospital, Duke-National University of Singapore (NUS) Medical School, Singapore.
Franck E NicoliniCentre Hospitalier Lyon-Sud, Pierre-Bénite, Lyon, France.
Jane F ApperleyCentre for Haematology, Imperial College, London, United Kingdom.
H Jean KhouryWinship Cancer Institute of Emory University, Atlanta, GA.
Moshe TalpazComprehensive Cancer Center, University of Michigan, Ann Arbor, MI.
Daniel J DeAngeloDana-Farber Cancer Institute, Boston, MA.
Elisabetta AbruzzeseS. Eugenio Hospital, Tor Vergata University, Rome, Italy.
Delphine ReaService d'Hématologie Adulte et Centre d'Investigation Clinique, Hôpital Saint Louis, Paris, France.
Michele BaccaraniDepartment of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy.
Martin C MüllerIII. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany.
Carlo Gambacorti-PasseriniUniversity of Milano-Bicocca/San Gerardo Hospital, Monza, Italy.
Stephanie LustgartenARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Victor M RiveraARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Frank G HaluskaARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
François GuilhotCentre d'Investigation Clinique (CIC) 1402, INSERM, Poitiers, France.
Michael W DeiningerHuntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Andreas HochhausHematology/Oncology, Jena University Hospital, Jena, Germany.
Timothy P HughesUniversity of Adelaide/South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia; and.
Neil P ShahDepartment of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA.
Hagop M KantarjianThe University of Texas MD Anderson Cancer Center, Houston, TX.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1
Indexed as
Philadelphia ChromosomeSalvage TherapyAdultAgedAged, 80 and overAntineoplastic AgentsDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPrognosisPyridazinesAntineoplastic AgentsImidazolesponatinibPyridazines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01207440ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.